JP2009511517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511517A5 JP2009511517A5 JP2008534900A JP2008534900A JP2009511517A5 JP 2009511517 A5 JP2009511517 A5 JP 2009511517A5 JP 2008534900 A JP2008534900 A JP 2008534900A JP 2008534900 A JP2008534900 A JP 2008534900A JP 2009511517 A5 JP2009511517 A5 JP 2009511517A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- different
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000004122 cyclic group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- -1 pentafluorosulfanyl Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048897A DE102005048897A1 (de) | 2005-10-12 | 2005-10-12 | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| PCT/EP2006/009577 WO2007042178A1 (de) | 2005-10-12 | 2006-10-04 | Diacylindazol-derivate als inhibitoren von lipasen und phospholipasen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511517A JP2009511517A (ja) | 2009-03-19 |
| JP2009511517A5 true JP2009511517A5 (US20070167479A1-20070719-C00034.png) | 2009-11-26 |
Family
ID=37813518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534900A Abandoned JP2009511517A (ja) | 2005-10-12 | 2006-10-04 | リパーゼおよびホスホリパーゼのインヒビターとしてのジアシルインダゾール誘導体 |
Country Status (18)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2389992T3 (es) | 2007-11-02 | 2012-11-05 | Vertex Pharmaceuticals Incorporated | Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| JP5605844B2 (ja) * | 2008-10-17 | 2014-10-15 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| US8754113B2 (en) | 2009-12-15 | 2014-06-17 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012031383A1 (zh) * | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9493412B2 (en) | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| US9249096B2 (en) | 2011-09-27 | 2016-02-02 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| US8993557B2 (en) | 2011-09-30 | 2015-03-31 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
| WO2013048942A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
| EP2760834B1 (en) | 2011-09-30 | 2016-11-16 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
| WO2013151923A1 (en) | 2012-04-03 | 2013-10-10 | Bristol-Myers Squibb Company | Pyrimidinone carboxamides as inhibitors of endothelial lipase |
| US9199946B2 (en) | 2012-04-03 | 2015-12-01 | Bristol-Myers Squibb Company | Pyrimidinone carboxamide inhibitors of endothelial lipase |
| TW201408665A (zh) | 2012-07-09 | 2014-03-01 | 必治妥美雅史谷比公司 | 含磺醯基之苯并噻唑內皮脂酶抑制劑 |
| WO2014011461A1 (en) | 2012-07-09 | 2014-01-16 | Bristol-Myers Squibb Company | Amide or urea substituted benzothiazole derivatives as inhibitors of endothelial lipase |
| WO2014015088A1 (en) | 2012-07-19 | 2014-01-23 | Bristol-Myers Squibb Company | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| EP2895483A1 (en) | 2012-09-11 | 2015-07-22 | Bristol-Myers Squibb Company | Ketone linked benzothiazole inhibitors of endothelial lipase |
| WO2015105749A1 (en) | 2014-01-07 | 2015-07-16 | Bristol-Myers Squibb Company | Sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| EP3286195A1 (en) | 2015-04-17 | 2018-02-28 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| UY36630A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| WO2017214005A1 (en) | 2016-06-06 | 2017-12-14 | Bristol-Myers Squibb Company | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| CN110526898A (zh) * | 2018-05-25 | 2019-12-03 | 北京诺诚健华医药科技有限公司 | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372421B1 (en) * | 2000-06-13 | 2002-04-16 | Eastman Kodak Company | Photothermographic imaging element having improved contrast and methods of image formation |
| WO2003035005A2 (en) * | 2001-10-26 | 2003-05-01 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| US7262200B2 (en) * | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| DE602004023062D1 (en) * | 2003-03-31 | 2009-10-22 | Lilly Co Eli | 3-oxo-1,3-dihydro-indazol-2-carbonsäureamid derivate als phospholipase inhibitoren |
| DE102004005172A1 (de) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
-
2005
- 2005-10-12 DE DE102005048897A patent/DE102005048897A1/de not_active Withdrawn
-
2006
- 2006-10-04 RU RU2008114360/04A patent/RU2008114360A/ru not_active Application Discontinuation
- 2006-10-04 WO PCT/EP2006/009577 patent/WO2007042178A1/de active Application Filing
- 2006-10-04 BR BRPI0617222-9A patent/BRPI0617222A2/pt not_active IP Right Cessation
- 2006-10-04 EP EP06806017.7A patent/EP1937648B1/de active Active
- 2006-10-04 AU AU2006301591A patent/AU2006301591A1/en not_active Abandoned
- 2006-10-04 CA CA002625546A patent/CA2625546A1/en not_active Abandoned
- 2006-10-04 KR KR1020087008736A patent/KR20080048062A/ko not_active Application Discontinuation
- 2006-10-04 CN CNA2006800376850A patent/CN101282939A/zh active Pending
- 2006-10-04 JP JP2008534900A patent/JP2009511517A/ja not_active Abandoned
- 2006-10-05 TW TW095136995A patent/TW200728285A/zh unknown
- 2006-10-10 AR ARP060104444A patent/AR056686A1/es not_active Application Discontinuation
- 2006-10-11 UY UY29853A patent/UY29853A1/es not_active Application Discontinuation
-
2008
- 2008-03-06 ZA ZA200802105A patent/ZA200802105B/xx unknown
- 2008-04-07 IL IL190672A patent/IL190672A0/en unknown
- 2008-04-08 MA MA30823A patent/MA29856B1/fr unknown
- 2008-04-08 US US12/099,337 patent/US7772268B2/en not_active Expired - Fee Related
- 2008-04-18 NO NO20081878A patent/NO20081878L/no not_active Application Discontinuation
-
2010
- 2010-07-20 US US12/839,863 patent/US8357698B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511517A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2008114360A (ru) | Производные диацилиндазола как ингибиторы липаз и фосфолипаз | |
| JP2007519649A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2008119435A (ru) | Производные триазолопиридина в качестве ингибиторов липаз и фосфолипаз | |
| RU2008119460A (ru) | Производные карбамоилбензола в качестве ингибиторов липаз и фосфолипаз | |
| JP2019519598A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2014509647A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2018106483A (ru) | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr | |
| JP2008536884A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2019504050A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| JP2014037426A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2013138717A (ru) | Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе | |
| HRP20170964T1 (hr) | Tiadiazolidindioni kao inhibitori gsk-3 | |
| JP2011520792A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2015508092A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2007508360A5 (US20070167479A1-20070719-C00034.png) | ||
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
| ATE432926T1 (de) | Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung | |
| JP2007522162A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2014500235A5 (US20070167479A1-20070719-C00034.png) | ||
| WO2009017098A1 (ja) | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体 | |
| HRP20100409T1 (hr) | Derivati azolopiridin-2-ona kao inhibitori fosfolipaze | |
| JP2012515787A5 (US20070167479A1-20070719-C00034.png) |
